Li, Ge;
Shofer, Jane B.;
Rhew, Isaac C.;
Kukull, Walter A.;
Peskind, Elaine R.;
McCormick, Wayne;
Bowen, James D.;
Schellenberg, Gerard D.;
Crane, Paul K.;
Breitner, John C.S.;
Larson, Eric B.
Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease : [See editorial comments by Dr. Mary Hann pp 000–000)
: [See editorial comments by Dr. Mary Hann pp 000–000)
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Age‐Varying Association Between Statin Use and Incident Alzheimer's Disease : [See editorial comments by Dr. Mary Hann pp 000–000)
:
[See editorial comments by Dr. Mary Hann pp 000–000)
Contributor:
Li, Ge;
Shofer, Jane B.;
Rhew, Isaac C.;
Kukull, Walter A.;
Peskind, Elaine R.;
McCormick, Wayne;
Bowen, James D.;
Schellenberg, Gerard D.;
Crane, Paul K.;
Breitner, John C.S.;
Larson, Eric B.
imprint:
Wiley, 2010
Published in:Journal of the American Geriatrics Society
Description:
<jats:p><jats:bold>OBJECTIVES: </jats:bold> To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) ɛ4 allele.</jats:p><jats:p><jats:bold>DESIGN: </jats:bold> A cohort of cognitively intact elderly participants was assessed biennially for dementia and AD.</jats:p><jats:p><jats:bold>SETTING: </jats:bold> Community based.</jats:p><jats:p><jats:bold>PARTICIPANTS: </jats:bold> Three thousand three hundred ninety‐two members of a health maintenance organization (HMO) aged 65 and older and without dementia.</jats:p><jats:p><jats:bold>MEASUREMENTS: </jats:bold> Statin use was identified from the HMO pharmacy database, and proportional hazards models were applied with statin use as a time‐dependent covariate to assess the association between statins and AD and the modifying effects of age and the APOE ɛ4 allele.</jats:p><jats:p><jats:bold>RESULTS: </jats:bold> Over an average of 6.1 years of follow‐up of 3,099 participants, 263 participants developed probable AD. The adjusted hazard ratio (aHR) for statin use was 0.62 (95% confidence interval (CI)=0.40–0.97) for AD in models including demographic characteristics and vascular risk factors as covariates. The strength of the association between statins and AD diminished with age (statin‐by–age at entry interaction <jats:italic>P</jats:italic>=.04); the aHR in those younger than 80 was 0.44 (95% CI=0.25–0.78), versus 1.22 (95% CI=0.61–2.42) for aged 80 and older. The interaction term for statin use–by–APOE ɛ4 was not significant (<jats:italic>P</jats:italic>=.65).</jats:p><jats:p><jats:bold>CONCLUSION: </jats:bold> This enlarged study confirms earlier findings that statin therapy in early old age, but not in late age, may be associated with a lower risk of AD. The relationship between statin use and AD was consistent across APOE genotypes.</jats:p>